Mutational separation and clinical outcomes of TP53 and CDH1 in gastric cancer

作     者：He-Li Liu Huan Peng Chang-Hao Huang Hai-Yan Zhou Jie Ge 

作者机构：Department of Gastrointestinal SurgeryXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Clinical Nursing Teaching and Research SectionXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Teaching and Research Section of Clinical NursingXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Department of PathologyXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina 

出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文版）（电子版）)

年 卷 期：2023年第15卷第12期

页      面：2855-2865页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by Guangdong Yiyang Healthcare Charity Foundation No.JZ2022014 

主　　题：Gastric cancer TP53 mutation CDH1 mutation Clinical outcome Somatic mutation Diffuse gastric cancer 

摘      要：BACKGROUND Gastric cancer(GC)is a deadly tumor with the fifth highest occurrence and highest global mortality *** to its heterogeneity,the underlying mechanism of GC remains unclear,and chemotherapy offers little benefit to *** To investigate the clinical outcomes of TP53 and CDH1 mutations in *** In this study,202 gastric adenocarcinoma tumor tissues and their corresponding normal tissues were collected.A total of 490 genes were identified using target *** t-test and Wilcoxon rank-sum test,somatic mutations,microsatellite instability,and clinical statistics,including overall survival,were detected,compared,and *** The mutation rates of 32 genes,including TP53,SPEN,FAT1,and CDH1 exceeded 10%.TP53 mutations had a slightly lower overall occurrence rate(33%).The TP53 mutation rate was significantly higher in advanced stages(stage Ⅲ/Ⅳ)than that in early stages(stage Ⅰ/Ⅱ)(P0.05).In contrast,CDH1 mutations were significantly associated with diffuse ***53 is related to poor prognosis of advanced-stage tumors;nevertheless,CDH1 corresponds to a diffuse type of ***53 is exclusively mutated in CDH1 and is primarily affected by two distinct GC *** Different somatic mutation patterns in TP53 and CDH1 indicate two major mechanisms of GC.